自己免疫疾患診断の世界市場

世界の自己免疫疾患診断の市場規模は、2023年の148億米ドルから、予測期間中は3.9%のCAGRで推移し、2028年には179億米ドルの規模に成長すると予測されています。

技術別では、ELISAの部門が2023年の47億米ドルから、4.0%のCAGRで推移し、2028年には57億米ドルに達すると予測されています。また、間接免疫蛍光法 (IIF) の部門は2023年の39億米ドルから、3.9%のCAGRで推移し、2028年には47億米ドルに達すると予測されています。

当レポートでは、世界の自己免疫疾患診断の市場を調査し、市場および診断技術の概要、関連法規制、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、技術・特許の動向、パイプライン分析、ESGの展開、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

• 市場の見通し
• 市場サマリー

第3章 市場概要と定義

• 概要：自己免疫疾患の診断
• 酵素結合免疫吸着アッセイ (ELISA)
• 間接免疫蛍光法 (IIF)
• マルチプレックスイムノアッセイ
• ウェスタンブロット (免疫ブロット)
• その他の技術
• 適応症
• 関節リウマチ
• 全身性エリテマトーデス (SLE)
• 乾癬性関節炎
• 多発性硬化症
• 炎症性腸疾患
• 自己免疫疾患の診断に関する世界の規制構造
• テストの検証
• FDAの認可または承認
• 適正製造基準 (GMP)
• ラベルと説明書
• 市販後の監視
• 品質管理と品質保証
• 臨床的有用性と医療ガイドライン
• プライバシーとデータセキュリティ
• 規制シナリオ
• 北米の規制
• ラテンアメリカの規制
• アジア太平洋地域の規制

第4章 市場力学

• 市場力学
• 市場促進要因
• 市場抑制要因
• 市場機会

第5章 市場内訳：地域別

• 市場概要・ディスカッション
• 北米
• メキシコ
• カナダ
• 欧州
• ドイツ
• 英国
• フランス
• イタリア
• スペイン
• その他の欧州
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア・ニュージーランド
• その他のアジア太平洋地域
• その他の地域

第6章 市場内訳：性別

• 市場概要・ディスカッション
• 男性
• 女性
• 北米市場
• 欧州市場
• アジア太平洋市場
• その他の地域市場

第7章 市場内訳：適応症別

• 市場概要・ディスカッション
• 1型糖尿病
• 関節リウマチ
• 全身性エリテマトーデス (SLE)
• 乾癬/乾癬性関節炎
• 多発性硬化症
• 炎症性腸疾患
• その他

第8章 市場内訳：技術別

• 酵素免疫測定法 (ELISA)
• 地域市場
• 間接免疫蛍光法 (IIF)
• 地域市場
• イムノブロット
• 地域市場
• マルチプレックスイムノアッセイ
• 地域市場
• その他
• 地域市場

第9章 ESGの展開

• 環境
• 調査の実践
• サプライチェーンの持続可能性
• 廃棄物管理
• エネルギー効率
• 社会面
• ヘルスケアへのアクセス
• 患者の健康
• コミュニティエンゲージメント
• ガバナンス
• 倫理的なビジネスプラクティス
• 規制の遵守
• 取締役会の多様性
• 透明性と説明責任
• ケーススタディ
• Roche
• Rocheの持続可能性
• BCCによる総論

第10章 新しい動向と技術

第11章 競合情勢

• 概要
• 業界シナリオ
• 企業シェア

第12章 特許分析

第13章 パイプライン分析

• 臨床試験

第14章 M&Aとベンチャー資金調達の見通し

第15章 企業プロファイル

• ABBOTT
• BD BIOSCIENCES
• BECKMAN COULTER INC.
• BIOMERIEUX
• BIO-RAD (ABD SEROTEC)
• F. HOFFMANN-LA ROCHE AG
• QUEST DIAGNOSTICS INC.
• SIEMENS HEALTHCARE
• THERMO FISHER SCIENTIFIC INC.

第16章 付録：頭字語

List of Tables

• Summary Table : Global Market for Autoimmune Disease Diagnostics, by Technology, Through 2028
• Table 1 : Components of ELISA
• Table 2 : Process of ELISA
• Table 3 : Components of Immunofluorescence (IIF)
• Table 4 : Process of Immunofluorescence (IIF)
• Table 5 : Types of Agglutination Test
• Table 6 : Global Market for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 7 : North American Market for Autoimmune Disease Diagnostics, by Country, Through 2028
• Table 8 : European Market for Autoimmune Disease Diagnostics, by Country, Through 2028
• Table 9 : Asia-Pacific Market for Autoimmune Disease Diagnostics, by Country, Through 2028
• Table 10 : Rest of the World Market for Autoimmune Disease Diagnostics, by Country, Through 2028
• Table 11 : Global Market for Autoimmune Disease Diagnostics, by Gender, Through 2028
• Table 12 : North American Market for Autoimmune Disease Diagnostics, by Gender, Through 2028
• Table 13 : European Market for Autoimmune Disease Diagnostics, by Gender, Through 2028
• Table 14 : Asia-Pacific Market for Autoimmune Disease Diagnostics, by Gender, Through 2028
• Table 15 : Rest of the World Market for Autoimmune Disease Diagnostics, by Gender, Through 2028
• Table 16 : Global Market for Autoimmune Disease Diagnostics, by Indication, Through 2028
• Table 17 : Global Market for Autoimmune Disease Diagnostics for Type 1 Diabetes, by Region, Through 2028
• Table 18 : Global Market for Autoimmune Disease Diagnostics for Rheumatoid Arthritis, by Region, Through 2028
• Table 19 : Global Market for Autoimmune Disease Diagnostics for SLE, by Region, Through 2028
• Table 20 : Global Market for Autoimmune Disease Diagnostics for Psoriasis/Psoriatic Arthritis, by Region, Through 2028
• Table 21 : Global Market for Autoimmune Disease Diagnostics for Multiple Sclerosis, by Region, Through 2028
• Table 22 : Global Market for Autoimmune Disease Diagnostics for Inflammatory Bowel Disease, by Region, Through 2028
• Table 23 : Global Market for Autoimmune Disease Diagnostics for Other Disease Indications, by Region, Through 2028
• Table 24 : Global Market for Autoimmune Disease Diagnostics, by Technology, Through 2028
• Table 25 : Global Market for ELISA for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 26 : Global Market for Indirect Immunofluorescence (IIF) for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 27 : Global Market for Immunoblot for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 28 : Global Market for Multiplex Immunoassays for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 29 : Global Market for Other Technologies for Autoimmune Disease Diagnostics, by Region, Through 2028
• Table 30 : ESG Frameworks for the Global Autoimmune Disease Diagnostics Market
• Table 31 : Environmental (E) Factors in Autoimmune Disease Diagnostics
• Table 32 : Social Framework, Global Autoimmune Disease Diagnostics
• Table 33 : Social (S) Factors in Autoimmune Disease Diagnostics
• Table 34 : Governance (G) Factors in Autoimmune Disease Diagnostics
• Table 35 : Top Pharma Companies, ESG Ratings, 2022
• Table 36 : Sustainability at Roche, 2022
• Table 37 : Roche's Ten-Year Ambitions
• Table 38 : Global Autoimmune Disease Diagnostics Emerging Trends and Technologies
• Table 39 : Global Company Market Shares of Autoimmune Disease Diagnostics, 2022
• Table 40 : Patents on ELISA, 2018-Present
• Table 41 : Selected Manufacturer Patents on ELISA, 2018-Present
• Table 42 : Patents on Indirect Immunofluorescence, 2018-Present
• Table 43 : Selected Manufacturer Patents on Indirect Immunofluorescence, 2018-Present
• Table 44 : Patents on Western Blot, 2018-Present
• Table 45 : Selected Manufacturer Patents on Western Blot, 2018-Present
• Table 46 : Clinical Trials on Type 1 Diabetes Diagnostics, as of 2023
• Table 47 : Clinical Trials on Rheumatoid Arthritis Diagnostics, as of 2023
• Table 48 : Clinical Trials on Systemic Lupus Erythematosus Diagnostics, as of 2023
• Table 49 : Clinical Trials on Psoriasis Diagnostics, as of 2023
• Table 50 : Clinical Trials on Multiple Sclerosis Diagnostics, as of 2023
• Table 51 : Clinical Trials on Inflammatory Bowel Disease Diagnostics, as of 2023
• Table 52 : Global Autoimmune Disease Diagnostics Market: Mergers and Acquisitions, 2023
• Table 53 : Abbott: Product Information
• Table 54 : Abbott: Revenue, 2020-2022
• Table 55 : BD Biosciences: Product Information
• Table 56 : BD Biosciences: Revenue, 2020-2022
• Table 57 : Beckman Coulter Inc. (Danaher): Product Portfolio
• Table 58 : Danaher: Revenue, 2020-2022
• Table 59 : BioMerieux: Product Portfolio
• Table 60 : BioMerieux: Revenue, 2020-2022
• Table 61 : Bio-Rad: Product Portfolio
• Table 62 : Bio-Rad: Revenue, 2020-2022
• Table 63 : F. Hoffmann-La Roche AG: Product Portfolio
• Table 64 : F. Hoffmann-La Roche AG: Revenue, 2020-2022
• Table 65 : Quest Diagnostics: Revenue, 2020-2022
• Table 66 : Siemens Healthcare: Product Portfolio
• Table 67 : Siemens Healthcare: Revenue, 2020-2022
• Table 68 : Thermo Fisher Scientific: Product Portfolio
• Table 69 : Thermo Fisher Scientific: Revenue, 2020-2022
• Table 70 : Major Acronyms Used in This Report

List of Figures

• Summary Figure : Global Market Shares of Autoimmune Disease Diagnostics, by Technology Type, 2022
• Figure 1 : Enzyme-Linked Immunosorbent Assay (ELISA)
• Figure 2 : Indirect Immunofluorescence (IIF)
• Figure 3 : Western Blot (Immunoblot)
• Figure 4 : Rheumatoid Arthritis
• Figure 5 : SLE
• Figure 6 : Global Market Shares of Autoimmune Disease Diagnostics, by Region, 2022
• Figure 7 : North American Market Shares of Autoimmune Disease Diagnostics, by Country, 2022
• Figure 8 : European Market Shares of Autoimmune Disease Diagnostics, by Country, 2022
• Figure 9 : Asia-Pacific Market Shares of Autoimmune Disease Diagnostics, by Country, 2022
• Figure 10 : Global Market Shares of Autoimmune Disease Diagnostics, by Gender, 2022
• Figure 11 : North American Market Shares of Autoimmune Disease Diagnostics, by Gender, 2022
• Figure 12 : European Market Shares of Autoimmune Disease Diagnostics, by Gender, 2022
• Figure 13 : Asia-Pacific Market Shares of Autoimmune Disease Diagnostics, by Gender, 2022
• Figure 14 : Rest of the World Market Shares of Autoimmune Disease Diagnostics, by Gender, 2022
• Figure 15 : Global Market Shares of Autoimmune Disease Diagnostics, by Indication, 2022
• Figure 16 : Global Market Shares of Autoimmune Disease Diagnostics for Type 1 Diabetes, by Region, 2022
• Figure 17 : Global Market Shares of Autoimmune Disease Diagnostics for Rheumatoid Arthritis, by Region, 2022
• Figure 18 : Global Market Shares of Autoimmune Disease Diagnostics for SLE, by Region, 2022
• Figure 19 : Global Market Shares of Autoimmune Disease Diagnostics for Psoriasis/Psoriatic Arthritis, by Region, 2022
• Figure 20 : Global Market Shares of Autoimmune Disease Diagnostics for Multiple Sclerosis, by Region, 2022
• Figure 21 : Global Market Shares of Autoimmune Disease Diagnostics for Inflammatory Bowel Disease, by Region, 2022
• Figure 22 : Global Market Shares of Autoimmune Disease Diagnostics for Other Disease Indications, by Region, 2022
• Figure 23 : Global Market Shares of Autoimmune Disease Diagnostics, by Technology, 2022
• Figure 24 : Global Electricity Produced from Renewable Sources, 2017-2021
• Figure 25 : Global Recycled Waste, 2017-2021
• Figure 26 : Global CO₂ Emissions, 2017-2021
• Figure 27 : Global Company Market Shares of Autoimmune Disease Diagnostics, 2022

Highlights:

The global market for autoimmune disease diagnostics is estimated to increase from $14.8 billion in 2023 to reach $17.9 billion by 2028, at a compound annual growth rate (CAGR) of 3.9% from 2023 through 2028.

The global market for autoimmune disease diagnostics for ELISA segment is estimated to increase from $4.7 billion in 2023 to reach $5.7 billion by 2028, at a compound annual growth rate (CAGR) of 4.0% from 2023 through 2028.

The global market for autoimmune disease diagnostics for Indirect immunofluorescence (IIF) segment is estimated to increase from $3.9 billion in 2023 to reach $4.7 billion by 2028, at a compound annual growth rate (CAGR) of 3.9% from 2023 through 2028.

Report Scope:

This report aims to study the autoimmune disease diagnostics global market size comprehensively. Current and historical market revenues can be estimated based on the technology, by indication, gender and region.

Report Includes:

• 41 data tables and 30 additional tables
• An overview of the global market landscape related to the autoimmune disease diagnostics
• In-depth analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, as well as forecasts for 2028. This analysis includes projections of Compound Annual Growth Rates (CAGRs) spanning through 2028
• Evaluation of the current market size and revenue growth prospects specific to autoimmune disease diagnostics, accompanied by a comprehensive market share analysis categorized by technology, indication, gender, and geographical region
• Detailed description of autoimmune disorder & therapies, and causes such as intrinsic factors, environmental factors, and lifestyle factors, and insights into new diagnostic pathway for autoimmune and inflammatory disorders
• Discussion on role of bioinformatics and biomarkers on autoimmune disorder therapies and information on standardization of test results
• Coverage of new product launches in the therapeutics for autoimmune diseases and performance methods in the detection of autoimmune antibodies
• Coverage of emerging technologies in autoimmune disease diagnostics, recent developments, future opportunities, patent review, and ESG trends
• Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
• Detailed profiles of leading market participants, including Abbott, Beckman Coulter Inc., BioMerieux, Siemens Healthcare, F. Hoffmann-La Roche AG, and Thermo Fisher Scientific

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• What's New in This Update?
• Scope of Report
• Methodology
• Information Sources
• Secondary Research
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview and Definitions

• Overview: Autoimmune Disease Diagnostics
• Enzyme-|Linked Immunosorbent Assay (ELISA)
• Indirect Immunofluorescence (IIF)
• Multiplex Immunoassays
• Western Blot (Immunoblot)
• Other Technologies
• Indications
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus (SLE)
• Psoriatic Arthritis
• Multiple Sclerosis
• Inflammatory Bowel Disease
• The Global Regulatory Structure for Autoimmune Disease Diagnostics
• Test Validation
• FDA Clearance or Approval
• Good Manufacturing Practices (GMP)
• Labeling and Instructions
• Post-Market Surveillance
• Quality Control and Quality Assurance
• Clinical Utility and Medical Guidelines
• Privacy and Data Security
• Regulatory Scenario
• North American Regulations
• Latin American Regulations
• Asia-Pacific Regulations

Chapter 4 Market Dynamics

• Market Dynamics
• Market Drivers
• Market Restraints
• Market Opportunities

Chapter 5 Market Breakdown by Region

• Market Overview and Discussion
• North America
• Mexico
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Australia and New Zealand
• Rest of Asia-Pacific
• Rest of the World

Chapter 6 Market Breakdown by Gender

• Market Overview and Discussion
• Male
• Female
• North American Market by Gender
• European Market by Gender
• Asia-Pacific Market by Gender
• Rest of the World Market by Gender

Chapter 7 Market Breakdown by Indication

• Market Overview and Discussion
• Type 1 Diabetes
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus (SLE)
• Psoriasis/Psoriatic Arthritis
• Multiple Sclerosis
• Inflammatory Bowel Disease
• Other Indications

Chapter 8 Market Breakdown by Technology

• Enzyme-Linked Immunosorbent Assay (ELISA)
• Regional Markets
• Indirect Immunofluorescence (IIF)
• Regional Markets
• Immunoblot
• Regional Markets
• Multiplex Immunoassays
• Regional Markets
• Others
• Regional Markets

Chapter 9 ESG Development

• Introduction
• Environment
• Research Practices
• Supply Chain Sustainability
• Waste Management
• Energy Efficiency
• Social
• Access to Healthcare
• Patient Well-Being
• Community Engagement
• Governance
• Ethical Business Practices
• Compliance with Regulations
• Board Diversity
• Transparency and Accountability
• Case Study
• Roche
• Sustainability at Roche
• Concluding Remarks from BCC Research

Chapter 10 Emerging Trends and Technologies

• Introduction

Chapter 11 Competitive Landscape

• Overview
• Industry Scenario
• Company Shares

Chapter 12 Patent Analysis

• Patent Analysis by Manufacturer

Chapter 13 Pipeline Analysis

• Clinical Trials

Chapter 14 M&A and Venture Funding Outlook

• Introduction

Chapter 15 Company Profiles

• ABBOTT
• BD BIOSCIENCES
• BECKMAN COULTER INC.
• BIOMERIEUX
• BIO-RAD (ABD SEROTEC)
• F. HOFFMANN-LA ROCHE AG
• QUEST DIAGNOSTICS INC.
• SIEMENS HEALTHCARE
• THERMO FISHER SCIENTIFIC INC.

Chapter 16 Appendix: Acronyms